Based on the hollow fiber assay (HFA) developed by the  USNational Cancer Institute (NCI), and combined with the novel Microtube Array Membrane (MTAM) delivers anti-cancer drug solutions for personalized cancer treatment and commercial anti-cancer drug R&D. Our screening range of services brings unprecedented accuracy and translatability, at a fraction of the time and cost of conventional screening solutions.



Next generation rapid and reliable anti-cancer drug screening platform for Personalized Medicine

Learn More


High throughput, extremely rapid, excellent translatability and cost effective candidate drug molecule screening platform for your drug research and development 

Learn More


High translatability and rapid screening of target patient segment identification for your lead candidate drug

Learn More

Latest News


B2MC Taiwan-Top Ten finalist & Innovex 2019- Taiwan Innovation Award. An extremely successful event this year! And we are featured on

American Association for Cancer Research (AACR)  Annual Meeting 2019 @ Atlanta, Georgia, USA

An extremely successful participation of AACR 2019 with excellent exposure of our novel MTAM based HFA for anti-cancer drug screening. 


We are now on the evening news (Taiwan Daai news channel) in Taiwan! View on to understand our novel MTAM based hollow fiber assay technology; and how it is helping cancer patients